

**AMENDMENT TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1: (currently amended) A method for treating persons suffering from acute or chronic degenerative conditions or diseases of the eye which comprises administering a pharmaceutically effective amount of a histone deacetylase inhibitor, wherein said histone deacetylase inhibitor is selected from the group consisting of suberoylanilide hydroxamic acid (SAHA), MS-275, oxamflatin, trichostatin A, depsipeptides, and suberic bishydroxamate (SBHA), wherein the acute or chronic degenerative condition or disease of the eye is selected from the group consisting of: primary open angle glaucoma; dry AMD; RP; retinal detachment and tears; macular pucker; ischemia affecting the outer retina; cellular damage associated with diabetic retinopathy and retinal ischemia; damage associated with laser therapy (grid, focal, and panretinal) including photodynamic therapy (PDT); trauma; surgical (retinal translocation, subretinal surgery, or vitrectomy) or light-induced iatrogenic retinopathy; and preservation of retinal transplants.

Claim 2: (canceled)

Claim 3: (currently amended) The method of Claim **[[2]] 1** wherein the condition or disease is dry AMD.

Claim 4: (currently amended) The method of Claim **[[2]] 1** wherein the condition or disease is primary open angle glaucoma.

Claim 5: (previously presented) The method of claim 1, wherein the histone deacetylase inhibitor is SAHA.